Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.49 |
| ▸ | GRM6 | O15303 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.49 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124212 | 1.00 | SLC1A2 (0.50) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| Hydrochloric Acid SCHEMBL4810967 | 0.98 | SLC1A2 (0.49) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| SCHEMBL6697973 | 0.87 | GRM2 (0.67) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| Hydrochloric Acid SCHEMBL4810986 | 0.85 | SLC1A2 (0.66) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| Hydrochloric Acid SCHEMBL6699648 | 0.85 | GRM2 (0.65) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| SCHEMBL14564867 | 0.83 | SLC1A2 (0.46) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| SCHEMBL8354226 | 0.77 | SLC1A2 (0.44) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| SCHEMBL5690924 | 0.76 | SLC1A2 (0.46) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| Hydrochloric Acid SCHEMBL6469345 | 0.76 | HSD17B10 (0.37) | SLC1A2SLC1A1GRM8GRM6GRM2 | |
| Hydrochloric Acid SCHEMBL5841061 | 0.76 | HSD17B10 (0.37) | SLC1A2SLC1A1GRM8GRM6GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456221-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456221-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456221-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070265342-A1 | 2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid; glutamate receptor agonist; antidepressant, anxiolytic agent; psychological, and psychiatric disorders | COFFEY DAVID S | 2007-11-15 | — | — | US | disclosed |
| US-20070265342-A1 | 2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid; glutamate receptor agonist; antidepressant, anxiolytic agent; psychological, and psychiatric disorders | COFFEY DAVID S | 2007-11-15 | — | — | US | disclosed |
| US-20070265342-A1 | 2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid; glutamate receptor agonist; antidepressant, anxiolytic agent; psychological, and psychiatric disorders | COFFEY DAVID S | 2007-11-15 | — | — | US | disclosed |
| US-7256217-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256217-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256217-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1368304-B1 | PRODRUGS OF EXCITATORY AMINO ACIDS | LILLY CO ELI (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1368304-B1 | PRODRUGS OF EXCITATORY AMINO ACIDS | LILLY CO ELI (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20040121962-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1310482-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1310480-A1 | Prodrugs of excitatory amino acids | Eli Lilly & Company (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265342-A1 | 2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid; glutamate receptor agonist; antidepressant, anxiolytic agent; psychological, and psychiatric disorders | GRIN2C, GRM2, GRIN2A | SLC1A2 7/4885SLC1A1 29/4885GRM8 33/4885 |
| US-20040121962-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A1, SLC1A3 | SLC1A2 1/4885SLC1A1 2/4885GRM8 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.